Tag Archives: Big Pharma

Big Pharma's "Firepower" Effectively Dropped by 20% in 2013, Says Report

Although Big Pharma’s ‘firepower’ increased last year by $100 billion, it declined in comparison with that of Big Biotech and specialty pharma, according to a new report from EY. EY’s Firepower Index measures companies’ capacity for conducting M&A deals. Firepower is diminished as its market value, cash and equivalents fall or as its debt levels […]
Posted in Strategy | Also tagged , , , | Leave a comment

Prove It! Top Line Thoughts on Trends That Will Shape the Industry in 2014

Top Line Thoughts on 2014:  Prove It! Ten days in and the New Year already seems old.  Yet members of our Pharm Exec Editorial Advisory Board are still eager to share their top of line predictions on trends that will shape the industry’s business and reputational assets – forward and backward – over the busy […]
Posted in Biotech, Strategy | Also tagged , , , | Leave a comment

Fred Hassan: More Musings on the Biopharma Learning Curve

Hindsight can be a great teacher – but only if you have the self-awareness needed to adapt those learnings to the next business challenge, whose rough edges are by definition almost always “non-recurring.” In other words, because the circumstances of any setback are unique, the astute manager knows that recovery depends on recognizing that the […]
Posted in healthcare, leadership, People, R&D, Sales, Strategy | Also tagged , , , , | 2 Comments

Storytelling Partnerships – the New Face of Big Pharma Marketing

Doing deals with storytellers could be as important for pharma as collaborating with research scientists, writes Peter Houston. Leading advertising trade publication Ad Week ran an interesting feature on the ‘New Face of Big Pharma Marketing’ this week. The piece outlines the changes that Obamacare combined with public distrust of pharma is forcing on marketers, noting […]
Posted in E-Media, Europe, Guest Blog, Marketing, Op-Ed, Strategy | Also tagged , , , , , | Leave a comment

Teva Joins Top 10, “Face” of Big Pharma Changing

Teva’s accession to the exclusive group that is the Pharma Top 10 is further proof, according to IMS Health, that branded pharma needs to renounce its product-protected past and embrace the patient-led, specialty-focused future. As the first non-western, non-innovative-core company to enter pharma’s global Top 10, according to IMS Health research, Teva’s rise to prominence […]
Posted in Global, Strategy | Also tagged , , | 1 Comment
  • Categories

  • Meta